Long-term use of the approved Dravet syndrome therapy Fintepla (fenfluramine) safely and consistently reduces seizure frequency in children and…
Articles by Andrea Lobo, PhD
Health-related quality of life is low for parents of children with Dravet syndrome relative to the general public in…
Lundbeck agreed to acquire the company developing bexicaserin, an investigational treatment for seizures associated with Dravet syndrome and…
Longboard Pharmaceuticals has launched a Phase 3 clinical trial evaluating the efficacy and safety of bexicaserin, its investigational…
The Dravet Syndrome Foundation (DSF) is partnering with the Mason’s Movement Foundation to provide bereavement support to families who…
The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to Longboard Pharmaceuticals‘ bexicaserin to treat seizures…
Epidiolex (cannabidiol) can help to reduce seizure frequency in some adults with generalized or localized forms of epilepsy —…
Epygenix Therapeutics, the company developing EPX-100 (clemizole) as a potential add-on treatment for people with Dravet syndrome,…
Encoded Therapeutics has received clearance from U.S. and Australian regulatory agencies to launch Phase 1/2 clinical trials testing…
Adding Fintepla (fenfluramine) to anti-seizure treatment is associated with a more than five times higher chance of having a…